Medicina (Jul 2019)

Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis

  • Hiroaki Tsurumaki,
  • Toshiyuki Matsuyama,
  • Kazuma Ezawa,
  • Yasuhiko Koga,
  • Masakiyo Yatomi,
  • Haruka Aoki-Saito,
  • Kazuaki Chikamatsu,
  • Takeshi Hisada

DOI
https://doi.org/10.3390/medicina55070336
Journal volume & issue
Vol. 55, no. 7
p. 336

Abstract

Read online

A 56-year-old man with severe asthma underwent bronchial thermoplasty (BT). However, his asthma exacerbated and hypereosinophilia developed 2 months later, thus necessitating oral corticosteroid (OCS) therapy. Six months after BT, a diagnosis of severe asthma with eosinophilic chronic rhinosinusitis (ECRS) was made and benralizumab treatment was initiated; the blood eosinophil count subsequently decreased and lung function improved, thereby permitting OCS dose tapering. Surprisingly, benralizumab both reduced nasal polyps and ameliorated ECRS. Thus, benralizumab may be a useful drug for the rapid treatment of severe asthma with ECRS, especially in patients with hypereosinophilia.

Keywords